These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33808166)

  • 1. Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development.
    Vélez-Reyes GL; Koes N; Ryu JH; Kaufmann G; Berner M; Weg MT; Wolf NK; Rathe SK; Ratner N; Moriarity BS; Largaespada DA
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Williams KB; Largaespada DA
    Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
    Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
    Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors.
    Kobayashi D; Hirayama M; Komohara Y; Mizuguchi S; Wilson Morifuji M; Ihn H; Takeya M; Kuramochi A; Araki N
    J Biol Chem; 2014 Sep; 289(38):26314-26326. PubMed ID: 25092287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.
    Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E
    Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Chaney KE; Perrino MR; Kershner LJ; Patel AV; Wu J; Choi K; Rizvi TA; Dombi E; Szabo S; Largaespada DA; Ratner N
    Cancer Res; 2020 Nov; 80(21):4720-4730. PubMed ID: 32816910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.
    Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL
    Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.
    Rahrmann EP; Watson AL; Keng VW; Choi K; Moriarity BS; Beckmann DA; Wolf NK; Sarver A; Collins MH; Moertel CL; Wallace MR; Gel B; Serra E; Ratner N; Largaespada DA
    Nat Genet; 2013 Jul; 45(7):756-66. PubMed ID: 23685747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets for NF1-associated malignant peripheral nerve sheath tumor.
    Binobaid L; Masternak MM
    Rep Pract Oncol Radiother; 2020; 25(4):556-561. PubMed ID: 32494228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.
    Carroll SL
    Am J Pathol; 2016 Mar; 186(3):464-77. PubMed ID: 26740486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promise of signal transduction in genetically driven sarcomas of the nerve.
    Kim A; Pratilas CA
    Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation.
    Hirbe AC; Dahiya S; Friedmann-Morvinski D; Verma IM; Clapp DW; Gutmann DH
    Oncotarget; 2016 Feb; 7(7):7403-14. PubMed ID: 26859681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations.
    Carroll SL; Stonecypher MS
    J Neuropathol Exp Neurol; 2004 Nov; 63(11):1115-23. PubMed ID: 15581179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
    Dang I; DeVries GH
    J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation.
    Rhodes SD; He Y; Smith A; Jiang L; Lu Q; Mund J; Li X; Bessler W; Qian S; Dyer W; Sandusky GE; Horvai AE; Armstrong AE; Clapp DW
    Hum Mol Genet; 2019 Aug; 28(16):2752-2762. PubMed ID: 31091306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling.
    Carroll SL; Stonecypher MS
    J Neuropathol Exp Neurol; 2005 Jan; 64(1):1-9. PubMed ID: 15715079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
    Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
    Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.